All In Biotech

Drug Trial Radar · NCT00903422

Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

98

Actual

Start

May 14, 2009

Primary completion

Jun 26, 2012

Study completion Dec 5, 2013

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 18, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and tolerability of eltrombopag in the treatment of low platelet counts in adult subjects with advanced myelodysplastic syndrome (MDS), secondary acute myeloid leukemia after MDS (sAML/MDS), or de novo AML that are relapsed, refractory or ineligible to receive azacitidine, decitabine, intensive chemotherapy or autologous/allogeneic stem cell transplantation. This is a placebo-controlled study in which patients will receive study medication daily for 6 months, during which time the dose of study medication may be adjusted based upon individual platelet counts and bone marrow blast counts. All subjects will receive best standard of care (platelet transfusions, mild chemotherapy, cytokines, valproic acid, all-trans retinoic acid, ESAs or G-CSF) in addition to study medication. Subjects taking placebo may be allowed to crossover to eltrombopag treatment if a clinically and statistically significant improvement in bone marrow blast counts is seen in subjects treated with eltrombopag.

Conditions

  • Myelodysplastic Syndrome

Interventions

  • eltrombopag olamineDrug

    thrombopoietin receptor agonist

  • PlaceboOther

    Placebo tablets with no active pharmaceutical ingredient

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability parameters including non-hematological laboratory Grade 3/Grade 4 toxicities, change in bone marrow blast counts from baseline and adverse events reporting.Time frame: Approximately 46 months

Locations

65 sites in 11 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Santa Monica, California

  • GSK Investigational Site

    Stanford, California

  • GSK Investigational Site

    Coral Springs, Florida

  • GSK Investigational Site

    Lake Worth, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Detroit, Michigan

  • GSK Investigational Site

    Kansas City, Missouri

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Camden, New Jersey

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Greenville, South Carolina

  • GSK Investigational Site

    Memphis, Tennessee

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    New Braunfels, Texas

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    Arlington, Virginia

  • GSK Investigational Site

    Fairfax, Virginia

  • GSK Investigational Site

    Madison, Wisconsin

  • GSK Investigational Site

    Rio de Janeiro, Brazil

  • GSK Investigational Site

    Rio de Janeiro, Brazil

  • GSK Investigational Site

    Salvador, Estado de Bahia, Brazil

  • GSK Investigational Site

    Belo Horizonte, Minas Gerais, Brazil

  • GSK Investigational Site

    Koebenhavn Oe, Denmark

  • GSK Investigational Site

    Odense C, Denmark

  • GSK Investigational Site

    Bayonne, France

  • GSK Investigational Site

    Besançon, France

  • GSK Investigational Site

    Bobigny, France

  • GSK Investigational Site

    Caen, France

  • GSK Investigational Site

    Marseille, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Toulouse, France

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Stuttgart, Baden-Wurttemberg, Germany

  • GSK Investigational Site

    Ulm, Baden-Wurttemberg, Germany

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.